# US 2006/0153863 A1 · Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153863 A1
- Document ID: US20060153863A1
- Status: Published application
- Kind: A1
- Application number: 11/302,286
- Filed: 2005-12-14
- Published: 2006-07-13
- Earliest claimed: 1999-12-15
- Assignees: Neovacs
- Inventors: Daniel Zagury
- Web page: https://patentgrep.com/patent/US20060153863A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 9/0043: {Nose}
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 16/112: Retroviridae (F), e.g. leukemia viruses
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/541: {Mucosal route}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.

## Claims

### Claim 1

A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize or block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus (HPV) or from an immune system cell, said native E7 protein being locally immunosuppressive and/or angiogenic and said method comprising administering to a patient in need thereof, by the mucous membrane route, a vaccine pharmaceutical composition comprising:
(i) an active compound selected from the group consisting of:
said Immunosuppressive and/or angiogenic native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or also by adjuvant conditioning;
an inactive fragment of said immunosuppressive and/or angiogenic native E7 protein;
a DNA molecule encoding said immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; and
a DNA molecule encoding an inactive fragment of said immunosuppressive and/or angiogenic native E7 protein; and
(ii) an adjuvant of mucosal immunity.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the immunosuppressive and/or angiogenic native E7 protein originates from a HPV strain selected from the group consisting of HPV strain 16 and HPV strain 18.

### Claim 3 (depends on 1)

The method of claim 1, wherein said active compound consists of said immunosuppressive and/or angiogenic native E7 protein that has been chemically treated with a chemical reagent selected from the group consisting of an aldehyde, a carboxamide, a carboxymethyl or a maleimide.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the immunosuppressive and/or angiogenic native E7 protein originates from a HPV strain selected from the group consisting of HPV strain 16 and HPV strain 18.

### Claim 5 (depends on 1)

The method of claim 1, wherein said active compound consists of a protein mutant from said immunosuppressive and/or angiogenic native E7 protein.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the immunosuppressive and/or angiogenic native E7 protein originates from a HPV strain selected from the group consisting of HPV strain 16 and HPV strain 18.

### Claim 7 (depends on 1)

The method of claim 1, wherein said active compound consists of a DNA molecule encoding (i) said Immunosuppressive and/or anglogenic native E7 protein inactivated by at least 70% by mutation or (ii) an inactive fragment of said immunosuppressive and/or angiogenic native protein.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the immunosuppressive and/or angiogenic native E7 protein originates from a HPV strain selected from the group consisting of HPV strain 16 and HPV strain 18.

### Claim 9 (depends on 1)

The method of claim 1, wherein the properties of said immunosuppressive and/or angiogenic native E7 protein have been inactivated by at least 70% by a chemical treatment and wherein said chemical treatment is selected from the group consisting of formolation, carboxamidation, carboxymethylation, maleimidation or oxidation by oxygen bubbling.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the immunosuppressive and/or angiogenic native E7 protein originates from a HPV strain selected from the group consisting of HPV strain 16 and HPV strain 18.

### Claim 11 (depends on 1)

The method of claim 1, wherein the mucous membrane route is an oral mucous membrane route.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the immunosuppressive and/or angiogenic native E7 protein originates from a HPV strain selected from the group consisting of HPV strain 16 and HPV strain 18.
